ASH 2016: What To Watch in San Diego
Next week, researchers will meet in San Diego, California, at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition.
Next week, researchers will meet in San Diego, California, at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition to present data from hundreds of studies conducted for patients with hematologic malignancies and blood disorders.
Topics of interest at this year's ASH annual meeting include: phase 3 trials for lymphoma and other hematologic cancers, gene therapy/immunotherapy, stem cells, and sickle cell disease.
Clinicians should watch for the following 3 randomized phase 3 trials in patients with lymphoma, all of which met their primary endpoints:
- Abstract 613: Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study (ClinicalTrials.gov Identifier: NCT01332968)
- Abstract 182: Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous t cell lymphoma versus physician's choice (methotrexate or bexarotene): The phase 3 Alcanza study (ClinicalTrials.gov Identifier: NCT01578499)
- Abstract 145: Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: Final results of the randomized phase 3 LyMa trial of the Lysa/Goelams Group (ClinicalTrials.gov Identifier: NCT00921414)
Noteworthy phase 3 studies in patients with other hematologic malignancies include:
- Abstract 229: Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: Interim results of a phase 3 study (CLL M1 study of the German CLL Study Group) (ClinicalTrials.gov Identifier: NCT01556776)
- Late-breaking abstract 5: Results of the PERSIST-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients with myelofibrosis (MF) and platelet counts less than 100,000/µL (ClinicalTrials.gov Identifier: NCT02055781)
- Late-breaking abstract 1: Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autoHCT with len maintenance (TAM) and autoHCT with len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): Primary results from the randomized Phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial) (ClinicalTrials.gov Identifier: NCT01109004)
Two additional studies related to immunotherapy to be presented at the ASH meeting that may inform clinical practice are:
- Abstract 650: Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) (ClinicalTrials.gov Identifier: NCT02315612)
- Late-breaking abstract 6: Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): Results from the pivotal phase 2 ZUMA-1 (ClinicalTrials.gov Identifier: NCT02348216)
- Papers to be presented at: American Society of Hematology (ASH) 58th Annual Meeting & Exposition; December 3-6, 2016; San Diego, CA.